RxDoctor Payments Data

Anne Lewis

Gerontology · Des Moines, IANPI 1245433655

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 34 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 10 manufacturers reported payments, led by AbbVie at 39.4% of the total. Reporting peaked in 2023 at $406 and has fallen 76.2% since, to $97 in 2025.

$982in general payments, 2019–2025

Across 34 payments — averaging $28.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$387
  • Biogen$216
  • TG Therapeutics, Inc.$198
  • Pfizer$54
  • SK Life Science, Inc.$38
  • Biohaven Pharmaceutical Holding Company Ltd.$23
  • plus $65 from 4 others

What the payments were for

  • Food & beverage$982100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$982 in reported general payments places this provider in the 80th percentile of 28 gerontology providers in Iowa.

See all gerontology providers in Iowa

Medicare billing

Part B allowed, 2024
$25,755
Medicare patients
326
Services billed
438

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VumerityDiroximel Fumarate21$269,948
ZeposiaOzanimod Hydrochloride17$155,332
CopaxoneGlatiramer Acetate20$112,126
Dalfampridine ErDalfampridine51$22,880
Aimovig AutoinjectorErenumab-Aooe27$20,179
QuliptaAtogepant22$20,073
Lacosamide109$19,925
ZonisadeZonisamide13$17,162
MyrbetriqMirabegron19$12,892
NayzilamMidazolam12$10,271
Levetiracetam255$8,966
Ajovy AutoinjectorFremanezumab-Vfrm11$7,921
Carbamazepine ErCarbamazepine86$7,783
Divalproex Sodium62$4,887
Carbidopa-LevodopaCarbidopa/Levodopa69$4,102

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
BiogenVumerity$216$269,94821 claims
Teva Pharmaceuticals USA, Inc.Copaxone$16$112,12620 claims
AbbVieQulipta$387$20,07322 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 28 gerontology providers in Iowa.

Other gerontology in Des Moines

See the full list for Iowa

Where these figures come from

Is this you, or does something look wrong? →